Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00025441|
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : December 4, 2013
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating children with metastatic rhabdomyosarcoma or other malignant mesenchymal tumors.
|Condition or disease||Intervention/treatment||Phase|
|Ovarian Cancer Sarcoma Small Intestine Cancer||Biological: dactinomycin Biological: filgrastim Drug: carboplatin Drug: cyclophosphamide Drug: doxorubicin hydrochloride Drug: epirubicin hydrochloride Drug: etoposide Drug: ifosfamide Drug: vincristine sulfate Procedure: peripheral blood stem cell transplantation Radiation: radiation therapy||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||MMT 98 Study For Metastatic Disease Rhabdomyosarcoma And Other Malignant Soft Tissue Sarcoma Of Childhood|
|Study Start Date :||November 1998|
|Actual Study Completion Date :||March 2010|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00025441
|Study Chair:||Heather P. McDowell, MD||Royal Liverpool Children's Hospital, Alder Hey|
|Study Chair:||Annabel B.M. Foot||Bristol Royal Hospital for Children|
|Study Chair:||Christophe Bergeron||Centre Leon Berard|